Drugs / ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs
ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07660783 | Sep 2026 → Sep 2031 expected | bone marrow failure syndrome, hemoglobinopathy, hemophagocytic syndrome, immune dysregulation, autoimmunity, and autoinflammation +1 | Fred Hutchinson Cancer Center | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07660783 ↗ |
| Modality | Cell therapy | “healthy stem cells from a donor are infused into the patient” NCT07660783 ↗ |
| Route | Intravenous | “CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0” NCT07660783 ↗ |